Abstract:Polymer–drug conjugates (PDCs) have shown great promise in enhancing the efficacy and safety of cancer therapy. These conjugates combine the advantageous properties of both polymers and drugs, leading to improved pharmacokinetics, controlled drug release, and targeted delivery to tumor tissues. This review provides a comprehensive overview of recent developments in PDCs for cancer therapy. First, various types of polymers used in these conjugates are discussed, including synthetic polymers, such as poly(↋-caprolactone) (PCL), D-α-tocopheryl polyethylene glycol (TPGS), and polyethylene glycol (PEG), as well as natural polymers such as hyaluronic acid (HA). The choice of polymer is crucial to achieving desired properties, such as stability, biocompatibility, and controlled drug release. Subsequently, the strategies for conjugating drugs to polymers are explored, including covalent bonding, which enables a stable linkage between the polymer and the drug, ensuring controlled release and minimizing premature drug release. The use of polymers can extend the circulation time of the drug, facilitating enhanced accumulation within tumor tissues through the enhanced permeability and retention (EPR) effect. This, in turn, results in improved drug efficacy and reduced systemic toxicity. Moreover, the importance of tumor-targeting ligands in PDCs is highlighted. Various ligands, such as antibodies, peptides, aptamers, folic acid, herceptin, and HA, can be incorporated into conjugates to selectively deliver the drug to tumor cells, reducing off-target effects and improving therapeutic outcomes. In conclusion, PDCs have emerged as a versatile and effective approach to cancer therapy. Their ability to combine the advantages of polymers and drugs offers enhanced drug delivery, controlled release, and targeted treatment, thereby improving the overall efficacy and safety of cancer therapies. Further research and development in this field has great potential to advance personalized cancer treatment options.

Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (PDCs).

Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic

Peptide Drug Conjugates and Their Role in Cancer Therapy

Peptide-drug conjugates: A new paradigm for targeted cancer therapy

Peptide-Drug Conjugates: A New Hope for Cancer Management

Peptide-Drug Conjugate: A Novel Drug Design Approach

Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy

Engineering peptide drug therapeutics through chemical conjugation and implication in clinics

Innovative Design of Targeted Nanoparticles: Polymer–Drug Conjugates for Enhanced Cancer Therapy

'Renovation of old drugs' - can peptide drug conjugates lead the post-ADC era?

Novel Peptide Therapeutic Approaches for Cancer Treatment

Targeted in situ self-assembly augments peptide drug conjugate cell-entry efficiency

Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment

The Development of Peptide-Drug Conjugates (pdcs) Strategies for Paclitaxel

Rethinking nanoparticulate polymer-drug conjugates for cancer theranostics

Peptide cargo administration: current state and applications

Source and exploration of the peptides used to construct peptide-drug conjugates

Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems

Peptide-decorated polymeric nanomedicines for precision cancer therapy.

Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates

Polypeptides–Drug Conjugates for Anticancer Therapy